Physician profile
Li Zuo
NPI 1023225190
$1,791.84
in general payments reported to CMS, 2019-2025
16 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $129 · 2021: $229 · 2022: $369 · 2023: $295 · 2024: $263 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $381.48 | 2019-2025 | Dupixent |
| Abbvie INC. | $381.37 | 2021-2024 | Rinvoq |
| Pfizer INC. | $191.87 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $137.81 | 2024-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $129.25 | 2021-2025 | |
| Optinose US, INC. | $115.11 | 2019-2022 | |
| Alk-Abello, INC | $109.60 | 2019-2022 | |
| Pharming Healthcare, INC. | $100.33 | 2023 | Ruconest |
| Biocryst US Sales Co., LLC | $41.53 | 2022 | |
| Emd Serono, INC. | $41.25 | 2023 | Mavenclad |
| Phadia US INC. | $39.55 | 2022-2023 | Immunocap |
| Merck Sharp & Dohme LLC | $33.74 | 2021-2023 | |
| Kaleo, INC. | $31.32 | 2020-2021 | |
| Grifols USA, LLC | $22.79 | 2025 | Xembify |
| Glaxosmithkline, LLC. | $22.42 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Zuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.